IBRX
ImmunityBio, Inc.Company Information
- Company Name
- ImmunityBio, Inc.
- CIK
- CIK0001326110
- Category
- Large accelerated filer
- Ticker: Exchange
- IBRX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- IBRX
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-07-02
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 781,688
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 203,774,583
- Shares outstanding
- 1,050,070,000
- Ownership
- 19.41%
Earnings Market Reaction
- Filing date
- 2026-08-04
- Price on filing date
- —
- 1-month reaction
- 15.83%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nonrelated Party | - | - | - | - | - | - | 7 | -10 | 6 | 14 | 9 | -6 | ||||||
| Related Party | - | - | - | - | - | - | 7 | -10 | 6 | 14 | 9 | -6 | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 76 | 205 | 88 | 60 | 138 | 61 | 143 | 112 | 130 | 133 | 265 | 178 | ||||||
| Marketable Securities Current | 282 | 176 | 154 | 198 | 16 | 1 | 6 | 18 | 88 | 37 | 1 | 12 | ||||||
| Accounts Receivable Net Current | 53 | 43 | 43 | 32 | 22 | 17 | 2 | 4 | 1 | - | 0 | - | ||||||
| Inventory Net | 2 | 1 | 1 | 7 | 7 | 8 | 8 | 2 | 2 | - | 0 | - | ||||||
| Other Receivables Net Current | - | - | - | - | - | - | 0 | 1 | 1 | 2 | 2 | 2 | ||||||
| Prepaid Expense And Other Assets Current | - | 28 | 29 | 33 | 26 | 22 | 24 | 26 | 21 | 23 | 26 | 23 | ||||||
| Assets Current | 439 | 453 | 315 | 329 | 208 | 109 | 185 | 163 | 243 | 196 | 294 | 215 | ||||||
| Marketable Securities Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 1 | 1 | ||||||
| Property Plant And Equipment Net | 114 | 113 | 114 | 130 | 133 | 135 | 137 | 139 | 142 | 144 | 146 | 152 | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | - | - | - | - | - | - | 16 | 17 | 17 | 18 | ||||||
| Intangible Assets Net Including Goodwill | 12 | 13 | 14 | 14 | 15 | 15 | 16 | 16 | - | - | 17 | - | ||||||
| Inventory Noncurrent | 16 | 19 | 14 | - | - | - | 0 | - | - | - | - | - | ||||||
| Operating Lease Right Of Use Asset | 31 | 33 | 33 | 33 | 35 | 32 | 33 | 35 | 34 | 35 | 37 | 36 | ||||||
| Other Assets Noncurrent | - | - | - | - | - | - | 5 | 4 | 3 | 3 | 3 | 3 | ||||||
| Assets | 629 | 647 | 502 | 519 | 402 | 304 | 383 | 365 | 444 | 401 | 504 | 432 | ||||||
Liabilities Current | ||||||||||||||||||
| Notes Payable Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Accounts Payable And Other Accrued Liabilities Current | 56 | 48 | 47 | 44 | 36 | 28 | 41 | 44 | 35 | 33 | 43 | 65 | ||||||
| Operating Lease Liability Current | 8 | 8 | 8 | 7 | 7 | 7 | 7 | 7 | 6 | 6 | 5 | 4 | ||||||
| Liabilities Current | 77 | 68 | 62 | 57 | 51 | 49 | 55 | 61 | 62 | 54 | 58 | 90 | ||||||
| Other Long Term Notes Payable | - | - | - | - | - | - | 0 | 111 | 109 | 107 | 105 | 480 | ||||||
| Secured Long Term Debt | 415 | 404 | 325 | 316 | 307 | 296 | 284 | 274 | 263 | 163 | 155 | - | ||||||
| Convertible Long Term Notes Payable | - | - | - | - | - | - | 0 | 588 | 584 | 580 | 577 | 165 | ||||||
| Operating Lease Liability Noncurrent | 31 | 33 | 33 | 34 | 36 | 33 | 35 | 37 | 36 | 38 | 40 | 39 | ||||||
| Embedded Derivative Fair Value Of Embedded Derivative Liability | 24 | 23 | 20 | 18 | 19 | 21 | 26 | 19 | 21 | 38 | 35 | - | ||||||
| Warrants And Rights Outstanding | 352 | 308 | 84 | 115 | 67 | 9 | 9 | 18 | 65 | 110 | 119 | 39 | ||||||
| Other Liabilities Noncurrent | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | ||||||
| Liabilities | 1,674 | 1,516 | 1,001 | 1,042 | 972 | 894 | 871 | 1,109 | 1,142 | 1,092 | 1,090 | 843 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 3,516 | 3,462 | 3,197 | 3,135 | 3,014 | 2,893 | 2,885 | 2,571 | 2,532 | 2,404 | 2,375 | 2,316 | ||||||
| Retained Earnings Accumulated Deficit | -4,590 | -4,359 | -3,727 | -3,665 | -3,597 | -3,505 | -3,375 | -3,316 | -3,230 | -3,096 | -2,962 | -2,728 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 27 | 27 | 29 | 5 | 13 | 20 | 1 | 0 | -0 | -0 | 0 | 1 | ||||||
| Stockholders Equity | -1,047 | -869 | -500 | -523 | -570 | -591 | -489 | -745 | -697 | -692 | -586 | -412 | ||||||
| Minority Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities And Stockholders Equity | 629 | 647 | 502 | 519 | 402 | 304 | 383 | 365 | 444 | 401 | 504 | 432 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 1,650 | 1,650 | 1,650 | 1,350 | 1,350 | 1,350 | 1,350 | 1,350 | 1,350 | 1,350 | 1,350 | 900 | ||||||
| Common Stock Shares Issued | 1,053 | 1,047 | 1,012 | 985 | 916 | 854 | 853 | 697 | 692 | 677 | 671 | 668 | ||||||
| Shares Outstanding | 1,053 | 1,047 | 1,012 | 985 | 916 | 854 | 853 | 697 | 692 | 677 | 671 | 668 | ||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialImmunityBio, Inc. (IBRX) — SEC Financial Statements & Analysis
ImmunityBio, Inc. (IBRX) is a biological products, (no diagnostic substances) company, incorporated in DE. ImmunityBio, Inc. trades on Nasdaq as: IBRX. ImmunityBio, Inc. (IBRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, ImmunityBio, Inc. carries a market cap of $9.19B, a P/E ratio of -9.26x, a P/B ratio of -8.78x, a P/S ratio of 55.45x, an enterprise value of $9.53B, and an EV/EBITDA multiple of -40.53x. On profitability, it posts a gross margin of 99.34%, an operating margin of -151.88%, a net margin of -598.54%, a Return on Equity (ROE) of 122.78%, a Return on Assets (ROA) of -192.58%, and a Return on Invested Capital (ROIC) of -1084.84%. Per share, it reports EPS of $-0.95, diluted EPS of $-0.95, free cash flow per share of $-0.27, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 192.92% year-over-year, net income growth of 170.31% year-over-year, and EPS growth of 128.64% year-over-year. On the balance sheet, it maintains a current ratio of 5.72x, a quick ratio of 5.70x, working capital of $362.25M, a debt-to-equity ratio of -1.60x, a debt ratio of 2.66, an interest coverage ratio of -4.29x, free cash flow of $-288.07M (TTM), and net debt of $339.42M. Figures sourced from SEC EDGAR.
- Market Cap
- $9.19B
- P/E TTM
- -9.26x
- EPS TTM
- $-0.95
- P/B TTM
- -8.78x
- ROE TTM
- 122.78%
- ROA TTM
- -192.58%
- Debt To Equity
- -1.60x
- Free Cash Flow TTM
- $-288.07M
- Net Revenue TTM Growth 1Y
- 192.92%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ImmunityBio, Inc. in?
ImmunityBio, Inc. (IBRX) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does IBRX trade on?
ImmunityBio, Inc. (IBRX) trades on the Nasdaq.
Where is ImmunityBio, Inc. incorporated?
ImmunityBio, Inc. is incorporated in DE.
When was ImmunityBio, Inc. (IBRX)'s most recent SEC filing?
ImmunityBio, Inc. (IBRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04.
What is IBRX's market cap?
ImmunityBio, Inc. (IBRX) has a market capitalization of $9.19B as of 2026-06-30.
What is IBRX's EPS (earnings per share)?
ImmunityBio, Inc. (IBRX)'s trailing twelve month EPS is $-0.95 as of 2026-06-30.
What is IBRX's ROE (return on equity)?
ImmunityBio, Inc. (IBRX)'s trailing twelve month Return on Equity (ROE) is 122.78% as of 2026-06-30.
What is IBRX's ROA (return on assets)?
ImmunityBio, Inc. (IBRX)'s trailing twelve month Return on Assets (ROA) is -192.58% as of 2026-06-30.
What is IBRX's ROIC (return on invested capital)?
ImmunityBio, Inc. (IBRX)'s trailing twelve month Return on Invested Capital (ROIC) is -1084.84% as of 2024-06-30.
What is IBRX's EV/EBITDA?
ImmunityBio, Inc. (IBRX)'s trailing twelve month EV/EBITDA is -40.53x as of 2026-06-30.